Snapshot from Nov 22, 2026 at 07:00 UTC. For live data and tracking: View Live
Tech medical study

Paracetamol raises blood pressure study

Analysis based on 7 articles · First reported Sep 01, 2026 · Last updated Sep 07, 2026

Sentiment
-10
Attention
2
Articles
7
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard

The study may influence prescribing practices for paracetamol, potentially reducing long-term use among hypertension patients and shifting some demand to alternative pain management. Pharmaceutical companies that market paracetamol could face reputational and sales pressure, while healthcare systems may see changes in chronic pain treatment protocols.

Pharmaceuticals Healthcare

A University of Edinburgh study, published in the scientific journal Circulation, found that regular use of paracetamol increases blood pressure in patients with hypertension. The randomized clinical trial involved 110 patients with a history of high blood pressure who were prescribed one gram of paracetamol four times a day or a placebo for two weeks. Those taking paracetamol saw a significant increase in blood pressure compared to placebo, an effect similar to that of NSAIDs and potentially increasing the risk of heart disease or stroke by about 20%. The findings challenge the long-held view that paracetamol is a safer painkiller for people with high blood pressure. Experts, including Professor Jim Dear and Dr Iain Macintyre, emphasized that short-term use is fine but regular long-term use carries risks. The British Heart Foundation funded the study, and its medical director, Professor Sir Nilesh Samani, called for regular reviews of long-term prescriptions. Blood Pressure UK's CEO Phil Pyatt also warned about the hidden sodium in soluble paracetamol. The study suggests that patients and doctors should weigh risks and benefits, and consider lower doses or alternatives for chronic pain management.

ngo
As the funder, the charity gains visibility for supporting important cardiovascular research. The findings align with its mission to prevent heart disease.
Importance 80.0 Sentiment 20.0
per
As a professor and spokesperson, he communicated the study's implications, raising awareness among medical professionals and the public.
Importance 70.0 Sentiment 10.0
per
Lead investigator who provided clinical context, distinguishing short-term from long-term risks, and contributed to the study's credibility.
Importance 60.0 Sentiment 10.0
per
As medical director, he endorsed the study's implications, urging regular medication reviews, which could influence clinical practice.
Importance 60.0 Sentiment 10.0
govactor
The national health service may need to update guidance on paracetamol prescribing and inform patients about the risks, potentially affecting public health outcomes.
Importance 60.0 Sentiment 10.0
govactor
Affiliated with the lead investigator, the health board may see changes in prescribing practices for paracetamol among its patients.
Importance 50.0 Sentiment 10.0
ngo
The charity highlighted the risks, especially the sodium content in soluble paracetamol, and called for awareness among patients and healthcare providers.
Importance 50.0 Sentiment 10.0
cnt
The study has implications for public health in the UK, where millions have high blood pressure and many take paracetamol regularly. It may lead to changes in prescribing and patient education.
Importance 50.0 Sentiment 0.0
per
As CEO, he added a public health warning about soluble paracetamol's sodium content, potentially affecting consumer choices.
Importance 40.0 Sentiment 10.0
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.